STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2021-09-21
Sep 21, 2021C
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome injection
- +2 more
- (no location specified)
2021-09-13
Sep 13, 2021H
Recruiting
- Glioblastoma
- Bortezomib and Temozolomide Phase IB
- Bortezomib and Temozolomide Phase II
- Bergen, Norway
- +1 more
2021-08-24
Aug 24, 2021M
U
Completed
- Multiple Myeloma
- Vorinostat Velcade Dexamethasone
- Nottingham, Nottinghamshire, United Kingdom
- +1 more
2021-08-09
Aug 9, 2021M
E
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- Dexamethasone
- Rionero in Vulture, Potenza, ItalyIrccs Crob
2021-02-04
Feb 4, 2021P
Recruiting
- Autoimmune Hemolytic Anemia
- Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
- combination of a single dose anti-CD20 antibody and bortezomib
- Beijing, Beijing, ChinaPeking Union Medical College Hospital
2021-10-12
Oct 12, 2021N
Completed
- Lung Diseases, Interstitial
- +2 more
- Bortezomib
- +2 more
- Chicago, IllinoisNorthwestern University
2021-08-02
Aug 2, 2021M
Completed
- Relapsed or Refractory Multiple Myeloma
- Vorinostat
- +2 more
- (no location specified)
2021-03-05
Mar 5, 2021U
Active, not recruiting
- Waldenström's Macroglobulinemia
- Dexamethasone, Rituximab, Cyclophosphamide
- Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
- Ulm, GermanyUniversity Hospital Ulm
2021-05-03
May 3, 2021S
Recruiting
- Antibody-mediated Rejection
- Bortezomib
- Tehran, Iran, Islamic Republic ofSBMU
2020-12-30
Dec 30, 2020N
Recruiting
- Neoplasms
- +2 more
- Bortezomib plus Clofarabine
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2021-09-02
Sep 2, 2021P
Recruiting
- Diffuse Large B Cell Lymphoma
- Ibrutinib and Bortezomib + R-CHOP
- Berlin, GermanyCharité - Universitätsmedizin Berlin, Hematology, Oncology and T
2021-01-25
Jan 25, 2021P
Recruiting
- Amyloidosis; Systemic
- Daratumumab
- +2 more
- Beijing, ChinaPeking Union Medical College Hospital
2021-05-31
May 31, 2021M
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
- Rochester, MinnesotaMayo Clinic in Rochester
2021-10-06
Oct 6, 2021H
Recruiting
- Hematological Malignancy
- Bortezomib
- Detroit, MichiganHenry Ford hospital
2020-11-03
Nov 3, 2020E
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
- Atlanta, GeorgiaEmory University Winship Cancer Institute
2021-11-01
Nov 1, 2021D
Terminated
- Waldenstrom's Macroglobulinemia
- Everolimus
- +2 more
- Boston, MassachusettsDana-Farber Cancer Institute
2021-04-22
Apr 22, 2021R
Terminated
- Follicular Lymphoma
- Bortezomib and Tositumomab I-131
- Chicago, IllinoisRush University Medical Center
2021-10-06
Oct 6, 2021J
Completed
- Acute Myelogenous Leukemia
- Bortezomib
- Doxil
- Sacramento, CaliforniaUniversity of California Comprehensive Cancer Center
2021-02-04
Feb 4, 2021S
Completed
- Multiple Myeloma
- Bortezomib
- +2 more
- Westwood, KansasThe University of Kansas Medical Center
2021-05-24
May 24, 2021A
Completed
- Chronic Antibody-mediated Transplant Rejection
- Bortezomib
- Plasma exchanges and intravenous immunoglobulins
- Paris, FranceHopital Necker Enfants-malades
2020-09-14
Sep 14, 2020M
Active, not recruiting
- Multiple Myeloma
- High-Risk Cancer
- Bortezomib following nonmyeloablative allogeneic transplant
- Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
2021-02-23
Feb 23, 2021U
Recruiting
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Bortezomib
- Ruxolitinib
- Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
2021-02-10
Feb 10, 2021